Neurocrine Biosciences
NBIXNeurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbena …
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2024-2026
All insider trades at Neurocrine Biosciences
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 5/19/2026 | Sell | Gorman, Kevin Charles | Director | $154.3 | $37,824,872 |
| 5/15/2026 | Sell | Pops, Richard F. | Director | $157.7 | $2,364,761 |
| 5/12/2026 | Sell | Norwalk, Leslie V. | Director | $155.0 | $590,601 |
| 1/16/2026 | Sell | Gano, Kyle | Chief Executive Officer | $132.7 | $4,830,458 |
| 12/16/2025 | Sell | Norwalk, Leslie V. | Director | $155.1 | $184,558 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)